Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II weekly cisplatin + oral vinorelbine with concurrent radiotherapy in elderly non-operable stage III NSCLC
2009-012413-21Phase 2Completed
- Sponsor
- CHU de Limoges
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin and vinorelbine in non-small cell lung cancer (NSCLC), sponsored by CHU de Limoges. Primary endpoint: Grade 3–4 non-gastrointestinal toxicity and grade 4 hematologic toxicity plus asthenia. Started Jun 2009; status: completed.
02
Drugs
cisplatinvinorelbine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2009-012413-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012413-21.